← Leaderboards
Martin K. Childers
University Of Missouri-Columbia
$7,329,077
Attributed
$7,329,077
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,329,077 · 7
By mechanism
R01$3,932,814 · 1
R44$1,824,229 · 2
R21$725,267 · 2
K18$464,137 · 1
K08$382,630 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Lisa Sattenspiel$130,872
- Dana M Schmidt$3,935
- Taylor Van Doren$322,129
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesAnimal ModelMuscleClinical TrialsDoseGene TherapyPhysiologicalAffectPhenotypeMutationPathologyCanis FamiliarisBiodistributionMolecularMediatingMutantCessation Of LifeDystrophinMaleResponseAdeno-Associated Viral VectorAnimalsBiopsyEffective Therapy
Grant awards (18)
Development of novel genetic medicine approaches to treat orphan diseases$1,159,305
R44 · FY2025 · AR · contact PI
Scalable Non-viral Gene Delivery for Neuromuscular Diseases$306,859
R44 · FY2025 · AR · contact PI
Development of novel genetic medicine approaches to treat orphan diseases$55,000
R44 · FY2025 · AR · contact PI
Development of novel genetic medicine approaches to treat orphan diseases$303,065
R44 · FY2024 · AR · contact PI
Gene therapy in canine myotubular myopathy for clinical translation$769,687
R01 · FY2017 · HL · contact PI
Gene therapy in canine myotubular myopathy for clinical translation$782,681
R01 · FY2016 · HL · contact PI
Gene therapy in canine myotubular myopathy for clinical translation$779,506
R01 · FY2015 · HL · contact PI
Gene therapy in canine myotubular myopathy for clinical translation$780,334
R01 · FY2014 · HL · contact PI
Gene therapy in canine myotubular myopathy for clinical translation$820,606
R01 · FY2013 · HL · contact PI
Establishing endpoints in canine myotubular myopathy for clinical translation$197,717
R21 · FY2013 · AR · contact PI
Establishing endpoints in canine myotubular myopathy for clinical translation$191,606
R21 · FY2012 · AR · contact PI
Induced Pluripotent Stem Cells in Canine Muscular Dystrophy$234,594
K18 · FY2011 · HL · contact PI
Induced Pluripotent Stem Cells in Canine Muscular Dystrophy$229,543
K18 · FY2010 · HL · contact PI
Leupeptin in a Canine Model of Duchenne Muscular Dystrophy$165,975
R21 · FY2006 · NS · contact PI
Leupeptin in a Canine Model of Duchenne Muscular Dystrophy$169,969
R21 · FY2005 · NS
MUSCLE RESPONSE TO STRESS IN CANINE MUSCULAR DYSTROPHY$127,546
K08 · FY2002 · HD
MUSCLE RESPONSE TO STRESS IN CANINE MUSCULAR DYSTROPHY$127,514
K08 · FY2001 · HD
MUSCLE RESPONSE TO STRESS IN CANINE MUSCULAR DYSTROPHY$127,570
K08 · FY2000 · HD